Apostrophe has been acquired by Hims & Hers Health, Inc.
The private shareholders of Apostrophe have sold the company to Hims & Hers Health, Inc.
Founded in 2012 and based in Oakland, California, Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized skincare brand and visionary leadership team, the company has experienced rapid growth over the past several years.
Based in San Francisco, California, Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.
Oaklins’ team in Los Angeles acted as advisor to the private shareholders of Apostrophe in this transaction.
Sprechen Sie mit dem Deal Team
Adam Abramowitz
Oaklins Intrepid
Hayden Rosenthal
Oaklins Intrepid
Transaktionen
Kaviari has received a minority investment from idiCo
Kaviari has received a minority investment from a pool of investors led by idiCo, alongside Bpifrance, IRD Invest and UI Investissement.
Mehr erfahrenAWC has acquired a significant minority stake in MyFitness
AWC AS, the investment company of the Norwegian family office Awilhelmsen, has acquired a 22.2% stake in MyFitness AS, the largest fitness club operator in the Baltics, becoming the MyFitness’ largest single shareholder.
Mehr erfahrenInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Mehr erfahren